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Abstract 
The current drug shortage crisis involving multiple oral antibiotics has significantly impacted preferred therapeutic options for 
treatment of H.pylori infection. Pharmacists may help alleviate the impact of this shortage through a proposed step-wise approach 
which includes proper inventory management, verification of indication, evaluation of regimen, therapeutic monitoring, and 




Helicobacter pylori (H. pylori) is a highly motile, curved, Gram-
negative rod found in the human stomach that is associated 
with numerous gastrointestinal health conditions including 
peptic ulcer disease (PUD), chronic gastritis, and gastric 
cancer.[1, 2] This pathogen, the only known bacterium to 
colonize the acidic human stomach, survives the harsh 
environment by producing urease. Production of this enzyme 
catalyzes the hydrolysis of urea to ammonia, thus elevating the 
pH of the stomach to neutral as needed for survival. In 
addition, H. pylori achieves further protection from the 
stomach environment by swimming to penetrate the mucus 
layer, attaching to epithelial cells, and ultimately causing 
inflammation.[3] This successful human pathogen is estimated 
to infect 50% of the global population.[4] The signs and 
symptoms associated with PUD are gnawing pain, burning 
discomfort, and tenderness in the epigastric area. H. pylori 
infection usually is transmitted via the gastro-oral or fecal-oral 
route. Many patients become colonized during early childhood 
and remain asymptomatic throughout their lives. Infection with 
H. Pylori has been associated with low socioeconomic status, 
increased age, crowding, and poor sanitation.[5] Increased 
levels of education may be a protective factor.[6] 
 
Treatment Options for H. Pylori 
A compilation of regimens published in February of 2012 
combined evidence from multiple sources including the 
American College of Gastroenterology (ACG) Guideline (2007), 
the Canadian Helicobacter Study Group Consensus (2004), and 
the Dyspepsia Working Group (2005) and found a total of 30 
known H. Pylori treatment regimens for adults.[7] 
 
The percentage of regimens in this compilation that contain 
one or more currently shorted drugs is high. Seven of these 30 
treatment regimens contain tetracycline (23%), two regimens 
utilize doxycycline, and 15 regimens contain clarithromycin 
(50%), despite recent data indicating clarithromycin resistance 
rates as high as 30%-40%. Three regimens include levofloxacin 
as the primary antibiotic, and one regimen contains rifabutin. 
Most of these regimens are combinations of a proton pump 
inhibitor (PPI) and 2 or 3 antibiotics to overcome antibiotic 
resistance. There are also two treatment regimens containing 
only one antibiotic (amoxicillin) but the efficacy of these 
combinations is low (70-77%) or unknown.[7] Figure 1 
illustrates the primary antimicrobial component of each of 
these 30 anti-H.pylori regimens. 
 
General therapy in the United States includes a PPI, 
clarithromycin, and amoxicillin or metronidazole (i.e. 
clarithromycin-based “triple therapy”) or a PPI or histamine 
type-2 receptor antagonist (H2RA), bismuth, metronidazole, 
and tetracycline (bismuth “quadruple therapy”).[1] Due to 
increasing resistance rates to clarithromycin, use of triple 
therapy regimens as first-line therapy is discouraged unless the 
regimen has been proven to be highly effective locally.[8, 9] 
 
Patients who undergo subsequent (salvage) treatment after 
demonstrating drug resistance to the initial prescribed H.pylori 
eradication regimen are less likely to achieve a successful 
outcome if they have been previously exposed to antibiotics in 
a treatment regimen, thus the greatest potential for 
eradicating H. pylori is through appropriate medication 
selection when choosing the first course of therapy.[1] Thus, 
the national drug shortage problem is further complicated by 
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drug resistance and underscores the importance of pharmacist 
involvement in antibiotic selection. 
 
Antibiotic Shortage: Implications for Patient Care 
The supply of tetracycline capsules has been affected by a drug 
shortage since July 2011. Both Teva Pharmaceuticals and 
Watson Pharmaceuticals have stated that all tetracycline 
capsules are temporarily unavailable due to shortage of the 
active ingredient and neither company can state a release 
date.[10, 11] Clarithromycin immediate-release tablets are in 
short supply due to either “an import ban on their products” 
(Ranbaxy Pharmaceuticals) or manufacturers (Abbot, Mylan, 
and Sandoz) stating they “could not provide a reason for the 
shortage”.[10] In addition, doxycycline hyclate capsules and 
tablets are backordered due to shortage of raw material 
(Mutual Pharmaceuticals), supply and demand (Watson and 
Heritage), or reason not provided (Lannett, Mylan, Par, 
VersaPharm, and West-Ward.)[12] These three shorted 
antibiotics are included in 25 of 30 (83%) of the 30 regimens 
described in Figure 1. 
 
Ramifications of untreated infections include persistence or 
exacerbation of the disease and the possibility of transmission 
to uninfected individuals. In cases of drug shortage or financial 
difficulty it is recommended to hold the antibiotic until the 
appropriate drugs become available, although a PPI can be 
administered for symptomatic treatment of ulcers.[13] 
 
Pharmacist Role: A Step-wise Approach 
We propose the following step-wise approach to management 
of antibiotic shortage in the treatment of H.pylori infection. 
1. Shortage validation and proper inventory management  
Pharmacists are often the first to recognize a looming drug 
shortage when unable to order an adequate supply, and are 
thus in the ideal position to implement a shortage 
management plan. The American Society of Health-System 
Pharmacists (ASHP) has published guidelines for managing drug 
shortages in hospitals and health systems recommending 
pharmacists take the lead in determining strategies and 
processes for dealing with the shortages.[14] Community-
based pharmacists can use the information contained in these 
guidelines to customize strategies for the outpatient setting as 
well. 
 
The first step in our approach is to confirm the cause and 
estimated duration of the drug shortage through contact with 
manufacturers or distributers. Information regarding 
manufacturing shortages is also available online through the 
Food and Drug Administration, Centers for Disease Control and 
Prevention, and the ASHP Drug Shortages page 
(www.ashp.org/shortages). After verifying the shortage, the 
pharmacist should next quantify all available inventory. 
Pharmacists in chain environments may borrow this strategy 
from their health system colleagues and conduct a chain-wide 
inventory to determine supply across the entire system. In 
addition, independently owned pharmacies may opt to use 
their networks to complete the inventory process potentially 
enabling pharmacists to provide patients with more options to 
fill needed prescriptions. 
 
Once the supply has been quantified and located, it is critical to 
determine the anticipated duration of the shortage using the 
same sources previously described. Using historical dispensing 
records and purchase history, pharmacists may predict the 
magnitude of the impact the shortage might have on the 
patient population served at the pharmacy. Once this 
information is known, pharmacists can begin developing 
strategies for managing the shortage for the expected duration. 
Options for pharmacists in health-system settings includes 
centralization of drugs in short supply within the pharmacy, 
sharing of repackaged sterile injectables for use within the 
same health-system, and educating prescribers on alternative 
agents for use.[15] Similarly, community pharmacists may 
consider restricting loaning or selling the product to other 
pharmacies, ordering through alternate distributors, stocking a 
variety of dosage forms or strengths, considering 
therapeutically equivalent products, and communicating 
information about the shortage to prescribers and patients. 
 
2. Verification of indication 
All pharmacists have the opportunity to verify the indication for 
any order or prescription for a medication in short supply in 
order to preserve the medication for those patients in greatest 
need. While this can be done more easily in the acute care 
setting through restrictions enforced by the medical staff of the 
hospital, the authors propose a similar method in the 
community setting where the pharmacist would take the lead 
in educating prescribers and patients about drug shortages and 
the importance of reserving inventory for those with 
compelling indications for use. Pharmacists who work in 
managed care organizations should facilitate alternative 
recommendations during times of prolonged drug shortage so 
as to minimize clinical and financial impact on patients. 
 
Pharmacists practicing in the community setting may be 
presented with a prescription regimen that does not have an 
indication but includes one of the shorted antibiotics. Shorted 
antibiotics, such as clarithromycin, may be dispensed in 
combination with other antibiotics as part of an H.pylori 
eradication regimen but may also be found in combination 
regimens for other indications (i.e. mycobacterial 
infection).[16] In this scenario, it is the opinion of the authors 
that community pharmacists may help address the antibiotic 
shortage by calling prescribers to confirm indication and 
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suggest an alternative regimen that does not include a shorted 
antibiotic, even in cases where the aforementioned antibiotic 
may be temporarily in stock. Pharmacists may not find 
physicians to be cooperative, however, as evidenced by an 
anticipated committee resolution to be introduced at the 
American Medical Association (AMA) 2013 meeting stating 
routine pharmacist inquiries “for verification of the rationale 
behind prescriptions, including diagnosis, treatment plan, ICD-9 
codes and/or previous medications/therapies that were 
tried/failed, and for routine pharmacist calls for such 
verification of this rationale, to be an inappropriate 
interference with the practice of medicine and 
unwarranted.”[17] In-house pharmacies, such as those found in 
community health centers, may have access to patient medical 
records and thus have the ability to confirm indication without 
a time-consuming, uncompensated call to the prescriber. 
 
3. Evaluate appropriateness of regimen 
Clinical, hospital, and community pharmacists have a shared 
responsibility to review H. Pylori orders for appropriateness of 
therapy. Pharmacists may improve the odds of treatment 
success by verifying that the prescribed treatment choice works 
locally (i.e. ≥90 or 95% success rate). It is possible that 
pharmacist recommendations for appropriate treatment may 
be in conflict with consensus statements when study results 
are not consistent with local treatment results, and 
pharmacists may find themselves recommending higher than 
usual doses of drugs (i.e. 500 mg of clarithromycin, 
metronidazole, and tetracycline) or longer durations (14 day) 
unless shorter durations have been shown locally to be equally 
effective. In addition, pharmacists should perform medication 
history reviews to confirm the patient has not recently taken 
the antibiotic included in the anti-H. pylori regimen in the past, 
and in the case of treatment failure, confirm drugs for which 
resistance is likely to have developed are not reused.[9] 
 
4. Patient and Provider Communication 
Pharmacists may employ a variety of methods to communicate 
with other health-care providers and patients regarding 
updates on the antibiotic shortage such as newsletters, fax 
announcements, and telephone calls. Research by Issets et al 
found that pharmacist collaboration with physicians can reduce 
drug cost and prevent errors.[18] Community pharmacists may 
also help reduce patient frustration with drug shortages by 
informing customers of drug shortages at the time of 
prescription drop-off and providing counseling on options for 
symptomatic relief of H.pylori-associated symptoms. 
 
Prescribers may call upon the pharmacist to suggest regimens 
that do not contain the shorted antibiotics, or may simply drop 
the shorted antibiotic from their prescribed regimen (i.e. 
changing quadruple therapy to triple therapy without evidence 
of efficacy). Only five of the 30 regimens compiled by the 
Pharmacist’s Letter utilize antibiotics other than the currently 
shorted tetracycline, clarithromycin, and doxycycline. These 
alternative regimens vary and may include amoxicillin alone or 
in combination with rifabutin or levofloxacin. However, these 
regimens should be considered potentially inadequate due to 
lack of efficacy data or data showing efficacy below the >80% 
(intention to treat) or >90% (per protocol) threshold.[7] 
 
5. Monitoring Therapy 
Last, pharmacists play an important role in monitoring 
treatment safety and efficacy. Pharmacists should counsel 
patients regarding adverse effects of antimicrobials associated 
with anti-H. Pylori regimens including carcinogenicity 
(metronidazole), disulfiram -like reactions (metronidazole), 
increased risk of tendinitis and tendon rupture 
(fluoroquinolones), and drug-drug interactions such as CYP3A 
induction (rifabutin).[9] Patient counseling regarding potential 
adverse effects of anti-H. pylori regimens is critical since poor 
adherence is an important predictor of treatment failure.[1] 
Ideally, all patients treated for H.pylori infection should receive 
testing to confirm eradication of infection, particularly those 
with H.pylori-associated ulcer or lymphoma, persistent 
dyspeptic symptoms, or who have undergone resection of early 
gastric cancer. Testing should be performed no sooner than 4 
weeks after completion of treatment, and options may include 
endoscopy, fecal antigen test (FAT), or urea breath test 
(UBT).[1] Pharmacists may also be called upon to counsel 
patients on point-of-care-testing (POCT) kits that detect IgG 
antibodies to H.pylori in whole blood. These kits are designed 
for professional in vitro diagnostic use only, but are available 
without a prescription over the internet.[19] 
 
Conclusion 
The step-wise approach outlined by the authors is one method 
to manage drug shortages to minimize the impact on patient 
care and models some successful strategies that have been 
used by health-system pharmacists for many years. In addition 
to the steps listed above, pharmacists may become advocates 
for drug shortages by sharing their frustrations and outlining 
opportunities for improvement with local, regional, and 
national legislators. For example, pharmacists may opt to 
obtain access to key politicians in their geographic area, pursue 
writing campaigns, or invite the politicians to their practice 
setting to observe how pharmacies operate during drug 
shortages.[20] The drug shortage crisis has resulted in a lack of 
first-line treatment regimens for H. pylori infection, and 
pharmacists in all practice settings are uniquely positioned to 




Original Research INSIGHTS 
 
http://z.umn.edu/INNOVATIONS                  2013, Vol. 4, No. 3, Article 124                               INNOVATIONS in pharmacy   4 
 
1. Chey WD, Wong B CY, et al. American College of 
Gastroenterology Guideline on the management of 
Helicobacter pylori infection. Am J Gastroenterol 
2007;102:1808-1825. 
2. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and 
Bennett's principles and practice of infectious diseases. 
Philadelphia, PA: Churchill Livingstone Elsevier; 2010. 
3. Celli JP, Turner BS, Afdhal NH, et al. Helicobacter pylori 
moves through mucus by reducing mucin viscoelasticity. 
PNAS 2009 Aug;106(34):14321-6. 
4. Malfertheiner P, Megraud F, O’Morain CA, et al. 
Management of Helicobacter pylori infection – the 
Maastricht IV/Florence Consensus Report. Gut 
2012;61:646-664. 
5. Smith JG, Li W, Rosson RS. Prevalence, clinical, and 
endoscopic predictors of Helicobacter pylori infection in an 
urban population. Conn Med 2009 Mar;73(3):133-7. 
6. Goodman KJ, O’Rourke K, Day RS, et al. Helicobacter pylori 
infection in pregnant women from a US-Mexico border 
population. J Immigr Health 2003 Jul;5(3):99-107. 
7. PL Detail-Document, H. Pylori Treatment Regimens for 
Adults. Pharmacist’s Letter/Prescriber’s Letter. February 
2012. 
8. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for 
Helicobacter pylori infections. Nat Rev Gastroenterol 
Hepatol 2011;8:79-88. 
9. Graham DY, Fischbach L. Helicobacter pylori treatment in 
the era of increasing antibiotic resistance. Gut 
2010;59:1143-1153. 
10. Drug shortages: current drugs. American Society of Health-
System Pharmacists. 
http://www.ashp.org/DrugShortages/Current/. Accessed 
on March 8, 2013. 
11. Current drug shortages S-Z. U.S. Food and Drug 
Administration. 
http://www.fda.gov/Drugs/DrugSafety/DrugShortages/uc
m314743.htm#tetracycline. Accessed on May 16, 2013. 
 
12. Doxycycline capsules and tablets. American Society of 
Health-System Pharmacists. 
http://www.ashp.org/DrugShortages/Current/Bulletin.asp
x?id=977. Accessed on June 18, 2013. 
13. PL Detail-Document,H. Pylori Treatment: An Update. 
Pharmacist’s Letter/Prescriber’s Letter. February 2012. 
14. Fox ER, Birt A, James KB, Kokko H, Salverson S, Soflin DL. 
ASHP Guidelines on Managing Drug Product Shortages in 
Hospitals and Health Systems. Am J Health Syst Pharm 
2009;66:1399-406. 
15. Drug shortages still at crisis levels. Drug Topics. 
http://drugtopics.modernmedicine.com/drug-
topics/news/drug-shortages-still-crisis-levels. Accessed on 
6/14/2013. 
16. Drug Facts and Comparisons. Wolters Kluwer Health. 
http://online.factsandcomparisons.com. Accessed on 
March 8, 2013. 
17. Houck, LK. AMA tells pharmacists: “Don’t call us we’ll call 
you.” Martindale-Hubbell. 
http://www.martindale.com/pharmaceuticals/article_Hym
an-Phelps-McNamara-PC_1839204.htm.  Accessed on 
6/19/2013. 
18. Issetts BJ, Brown LM, Schondelmeyer SW, et al. Quality 
assessment of a collaborative approach for decreasing 
drug-related morbidity and achieving therapeutic goals. 
Arch Intern Med 2003;163:1813-1820. 
19. Rapid response H.pylori test 15/bx. Pulmolab. 
https://www.pulmolab.com/hpylorirapidtest-p-544.html. 
Accessed on May 21, 2013. 
20. Thompson, CA. Pharmacist converted frustruation about 










Original Research INSIGHTS 
 




Fig. 1 - Distribution of the use of different antibiotic in H. Pylori treatment regimens 
 
 
 
